ARDELYX, INC. (ARDX) research
ARDELYX, INC.- Sector
- Biotechnology
- Last price
- $3.62
- As of
ARDELYX, INC. (ARDX): 5 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-08-17.
As of . Source: SEC EDGAR filings for ARDX. Method and limitations.
Share the ARDX intelligence card
See ARDX live in the terminal
Track ARDX's insider trades, 13F flows, options positioning, and cross asset confluence as they update, on one live board. Free account.
Open the live ARDX terminal, freeActive signals for ARDX
- highINSTITUTIONAL_EXIT
MILLENNIUM MANAGEMENT LLC cut 98% of ARDX (2026Q2)
- highINSTITUTIONAL_EXIT
MILLENNIUM MANAGEMENT LLC cut 100% of ARDX (2026Q2)
- highINSTITUTIONAL_SURGE
CITADEL ADVISORS LLC added +344% to ARDX (2026Q2)
- highINSTITUTIONAL_EXIT
CITADEL ADVISORS LLC cut 63% of ARDX (2026Q2)
- highINSTITUTIONAL_EXIT
D. E. Shaw & Co., Inc. cut 96% of ARDX (2026Q2)
FREE, NO ACCOUNT
Every signal on ARDX, as it fires
You are seeing 5 of 26 signals recorded on ARDX since 2026-06-10.
The five above all landed on 2026-09-06. The other 21 were recorded on 3 other days. 22 of the 26 are institutional flow rows, which arrive in batches on filing days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in ARDX (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| MILLENNIUM MANAGEMENT LLCCUSIP 039697107 · 2026Q2 | $70.9M | 0.03% | , |
| TWO SIGMA INVESTMENTS, LPCUSIP 039697107 · 2026Q2 | $26.6M | 0.02% | , |
| CITADEL ADVISORS LLCCUSIP 039697107 · 2026Q2 | $5.3M | 0.00% | , |
| RENAISSANCE TECHNOLOGIES LLCCUSIP 039697107 · 2026Q2 | $4.6M | 0.01% | , |
| D. E. Shaw & Co., Inc.CUSIP 039697107 · 2026Q2 | $67K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, ARDX
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
ARDX against its peers
ARDX's operating margin of -10.1% ranks in the 68th percentile of 10 Biotechnology sub-industry peers, fiscal period ending 2025-12-31.
| Metric | ARDX | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 407M USD | 42.7M USD | 96 | 11 |
| Operating margin | -10.1% | -229.1% | 68 | 10 |
| Net margin | -15.1% | -201.2% | 68 | 10 |
| Return on equity | -36.9% | -38.4% | 60 | 20 |
Peers (21): TBPH, AVTX, GERN, CLYM, IMMX, RIGL, OLMA, WVE, SGP, SANA, FDMT, CADL, DSGN, ACHV, SLDB, LXRX, GYRE, JANX, ANNX, DBVT, ABUS. Left out: IVA (period gap), ETRA (no annual filing), ANL (period gap), HELP (period gap). Fiscal period ending 2025-12-31. Every figure is one full fiscal year read from one annual filing (ARDX: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
See more ARDX signals as they fire
Kresmion publishes filings, 13F flows, on-chain whale activity, and cross-asset signals in real time. Open a live board scoped to ARDXand get the insider, 13F, options, and confluence read in one view.